SABR-Dual试验初始队列:两分次立体定向放疗联合直肠间隔的两年毒性与PSA动态
SABR-Dual试验初始I期队列纳入20例低危或预后良好中危前列腺腺癌患者,接受27 Gy/2次立体定向放疗(可选整合推量至30 Gy),均置入直肠间隔和水凝胶标记。两年结果显示毒性可接受,PSA较基线下降94.8%,但性功能领域的最小临床重要变化率在两年时仍达47.4%。
要点
- 两分次前列腺SABR联合直肠间隔的两年毒性和PSA反应良好。
- 两年时IPSS中位下降4分,SHIM中位下降1分。
- 性功能是唯一在两年时最小临床重要变化率未下降的EPIC-26领域。
核心结论
- 两分次前列腺SABR联合直肠间隔安全性可接受,具有可接受的中期毒性和优异的PSA反应。
研究设计与样本
- SABR-Dual试验初始I期队列,20例低危或预后良好中危前列腺腺癌患者接受27 Gy/2次立体定向放疗,可选整合推量至30 Gy,均置入不透射线水凝胶间隔和金标,采用MRI计划及实时金标追踪。
主要发现
- IPSS中位变化在1年时增加1分(IQR -1.5至6),2年时下降4分(IQR 0.5至8.5)。
- SHIM中位评分在1年和2年分别下降1分(IQR -4.5至0.5)和1分(IQR -6.5至0.5)。
- EPIC-26尿失禁、刺激/梗阻、肠道、性和激素症状领域的最小临床重要变化率在1年至2年间下降,但性功能领域例外,1年率为8/19(42.1%),2年率为9/20(47.4%)。
- 1年和2年1/2级泌尿毒性率分别为30%/30%和5%/20%,1/2级肠道毒性率分别为0%/10%和5%/5%。
- PSA均值和中位数从基线5.66和5.35 ng/mL降至1年时1.22和0.88 ng/mL、2年时0.42和0.31 ng/mL,分别代表下降81.3%和94.8%。
临床怎么用
- 两分次前列腺SABR联合直肠间隔可作为低危或预后良好中危前列腺癌的备选方案,需关注性功能保护。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We present the pre-planned co-secondary endpoint of two-year toxicity and early PSA response in the initial phase-I cohort of the SABR-Dual trial of two-fraction stereotactic radiotherapy (SABR) for localized prostate cancer. MATERIALS AND METHODS: 20 patients with favorable intermediate- or low-risk prostate adenocarcinoma received a dose of 27 Gy in two fractions, with an optional integrated boost to 30 Gy. All underwent radiopaque hydrogel spacer and fiducial placement. MRI-based planning and real-time fiducial tracking were applied. Pre-planned secondary endpoints of two-year patient-reported quality of life based on EPIC-26, International Prostate Symptom Score (IPSS), and Sexual Health Inventory for Men (SHIM) questionnaires, toxicity based on CTCAEv5.0 assessment, and temporal PSA dynamics, were analyzed. RESULTS: A median increase in IPSS of 1 (IQR, -1.5-6) occurred at one-year, with a median decrease of 4 (IQR, 0.5-8.5) at two-years. Median SHIM score decreased at one- and two-years by 1 (IQR, -4.5-0.5) and 1 (IQR, -6.5-0.5), respectively. Rates of minimally clinically important change in EPIC-26 subdomains of urinary incontinence, irritative/obstructive, bowel, sexual, and hormonal symptoms decreased between one- and two-years, with the exception of sexual function, with rates of 5/19 (26.3%), 5/19 (26.3%), 6/19 (31.5%), 8/19 (42.1%), and 3/19 (15.8%), at one-year, and 2/19 (10.5%), 3/19 (15.8%), 1/19 (5.3%), 9/20 (47.4%), and 0/19 (0%), at two-years, respectively. Rates of grades 1/2 urinary toxicity at one- and two-years were 30%/30% and 5%/20%, while rates of grades 1/2 bowel toxicity were 0%/10% and 5%/5%, respectively. Mean and median PSA decreased from 5.66 and 5.35 ng/mL at baseline to 1.22 and 0.88 ng/mL and 0.42 and 0.31 ng/mL at 1- and 2-year follow-up, respectively, representing a decrease of 81.3% and 94.8%. CONCLUSION: Two-fraction prostate SABR using rectal spacing appears safe with acceptable intermediate-term toxicity and excellent PSA response.
引用
- Fredman E, Attrash M, Yosefof E, et al. Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial - two-fraction stereotactic radiotherapy for localized prostate cancer using rectal spacing. Radiother Oncol. 2026. PMID: 41876028. doi:10.1016/j.radonc.2026.111497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。